CVOTs reinforce linagliptin’s cardiorenal safety profile in the management of T2D

24 Feb 2020
CVOTs reinforce linagliptin’s cardiorenal safety profile in the management of T2D
In a lecture tour series organised by Boehringer Ingelheim Malaysia, Professor Michael Cummings spoke on the latest linagliptin analyses that shed new light on the long-term safety profile of the dipeptidyl peptidase-4 (DPP-4) inhibitor across a broad range of patients with type 2 diabetes (T2D).

Related MIMS Drugs

Editor's Recommendations